Case Study Of Pfizer

Pfizer Market Share
Pfizer is one of the largest pharmaceutical companies in the world, its headquarter locates in the US. Pfizer financial report of its fourth-quarter claim a 3% decline in sales diverted to $13.12 billion from Q4 2013 and recording a 4% decline in adjusted profit per share to $0.54 [35]. The challenges that Pfizer face can be generalized to an industrial challenge and the global economic environment challenge [29]. For intellectual rights, Pfizer products, including BeneFIX, ReFacto, Xyntha and Enbrel will have to compete biosimilars (also referred to as follow-on biologics) in the future just when competitors obtain marketing approval for biosimilars or when patent expiated [29]. There are other challenges that put Pfizer

Nevertheless, Pfizer also pronounced that they are waiting to validate their review of the Marketing Authorization Application (MAA) for Ibrance by the European Medicines Agency (EMA) [33]. Again to promote Palbociclib in combination with endocrine therapy for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. Today, Ibrance expected to cost about $9,850 per month and it will cost about $ 167,000 for 17-month regimen [34]. The drug can be obtained from specialty pharmacy providers SPPs, or through a co-pay assistance that patients can apply to it through Pfizer RxPathways program [30]. We think if Ibrance approved by EMA and Pfizer start marketing Ibrance globally, their revenue will raise and so do their market share. In addition, we assume that if the oncology pipeline of Pfizer come up with more drug to treat other type of cancer undoubtedly the company will success facing their financial challenges. We recommended that Pfizer keep aware of two important things the raising of US dollar and the two candidate products of Eli Lilly’s LY2835219 and Novartis’s LEE011 that many over lead Ibrance in the coming two-years [33]. Theses two drugs are CDK inhibitor to as Ibrance